Heparin plays a key role in allergic and inflammatory reactions driven by mast cells, scientists have found.
The study, conducted by scientists from Karolinska Institutet in Sweden in collaboration with colleagues from Germany and Switzerland, sheds some new light on the biological function of heparin.
Professor Erik Jorpes Jorpes showed that heparin is produced in a specific blood-born cell population, called mast cells. Mast cells have a central function in allergic and inflammatory diseases and contribute to increased vascular permeability, allergic and anaphylactic reactions. The current study identifies the underlying mechanism and its therapeutical implications.
The authors show that heparin initiates the production of a hormone - bradykinin - that contributes to swelling, anaphylactic and inflammatory symptoms, which are commonly known to be associated with aberrant mast cell activity. Notably, mast cell-released heparin generates the inflammatory mediator bradykinin via activation of factor XII (the so-called Hageman Factor) that belongs to the blood coagulation system.
The study thus provides an unexpected link between the clotting cascade and mast cell-driven pro-inflammatory reactions. Drugs that block bradykinin or factor XII activity protect from adverse mast cell-driven effects in patients and genetically engineered mouse models and could be a new strategy to treat allergic diseases.
The study has been published in the recent issue of Immunity.